Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Menora Mivtachim Holdings LTD.'s 6th Largest Position

Menora Mivtachim Holdings LTD. lessened its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 1.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 28,381,242 shares of the company's stock after selling 456,797 shares during the period. Teva Pharmaceutical Industries makes up 3.9% of Menora Mivtachim Holdings LTD.'s investment portfolio, making the stock its 6th largest holding. Menora Mivtachim Holdings LTD. owned 2.51% of Teva Pharmaceutical Industries worth $625,523,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in TEVA. Diversify Advisory Services LLC increased its stake in shares of Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after purchasing an additional 496 shares in the last quarter. Sanctuary Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after buying an additional 664 shares during the period. Thrivent Financial for Lutherans lifted its holdings in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after buying an additional 699 shares in the last quarter. Townsquare Capital LLC boosted its stake in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after buying an additional 812 shares during the last quarter. Finally, Metis Global Partners LLC raised its stake in Teva Pharmaceutical Industries by 6.7% during the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after buying an additional 860 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Bank of America dropped their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. UBS Group dropped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Remove Ads

Teva Pharmaceutical Industries Stock Performance

TEVA stock opened at $13.42 on Friday. The company has a 50-day simple moving average of $15.79 and a 200 day simple moving average of $17.82. The company has a market capitalization of $15.22 billion, a P/E ratio of -9.26, a PEG ratio of 1.44 and a beta of 0.72. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.